替米沙坦联合舒洛地特治疗糖尿病肾病Ⅲ期临床观察

Abstract
Figure/Table
References (15)
Related Citation (3)

Download: PDF (0 KB) HTML (26 KB)
Export: BibTeX | EndNote (RIS)

Abstract ObjectiveTo investigate the clinical efficacy of Telmisartan combined with Sulodexide in the treatment of diabetic nephropathy.Methods64 patients with diabetic kidney disease at stageⅢtreated in our hospital from March 2015 to March 2017 were selected as subjects of this study.They were divided into control group and study group with random number table method,32 cases in each group.Two groups of patients were treated with conventional therapy,the patients of control group were given Telmisartan on the addition of conventional treatment,the patients of study group were given Telmisartan and Sulodexide on the basis of conventional treatment,all patients were treated for 8 weeks.The total effective rate of treatment,the serum creatinine(Scr),urea nitrogen(BUN),microprojection rate(UAER),high sensitivity C-reactive protein(hs-CRP)and tumor necrosis factor-α (TNF-α)before and after 8 weeks of treatmen were comapred between two groups.ResultsThe total effective rate in the study group(93.75%)was higher than that in the control group(68.75%),and the difference was statistically significant(P<0.05).There was no significant difference in the Scr,BUN and UAER between the two groups before treatment(P>0.05).After treatment,the UAER in both groups were lower than before treament,the UAER in the study group was significantly lower than that in the control group,and the difference was statistically significant(P<0.05).Before treatment,there was no statistically significant difference in hs-CRP and TNF-α in the two groups(P>0.05).After treatment,the levels of hs-CRP and TNF-α in both groups were significantly lower than before treatment,and the levels of hs-CRP and TNF-α in the study group were significantly lower than those in the control group,and the differences were statistically significant(P<0.05).ConclusionThe efficacy of Telmisartan combined with Sulodexide in the treatment of diabetic kidney disease is significantly better than that of telmisartan alone,and it is recommended to be widely used clinically.

Key words： Telmisartan Sulodexide Diabetic kidney disease Clinical observation

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	FANG Hai-ming

Cite this article:

FANG Hai-ming. Clinical observation of Telmisartan combined with Sulodexide for diabetic kidney disease at stageⅢ[J]. 中国当代医药, 2018, 25(5): 126-128.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2018/V25/I5/126

[1]	刘珊.舒洛地特联合贝那普利治疗糖尿病肾病临床观察[J].疑难病杂志，2011，10（1）：21-22.
[2]	王颖，燕树勋，吕久省.舒洛地特联合缬沙坦治疗糖尿病肾病（Ⅳ期）的临床观察[J].中华糖尿病杂志，2013，21（2）：136-138.
[3]	高俊杰，汪芳丽，王卫松，等.舒洛地特联合黄芪注射液治疗早期糖尿病肾病的临床观察[J].现代中西医结合杂志，2013，22（33）：3680-3682.
[4]	王蜀湘，胡延海.舒洛地特联合瑞格列奈治疗糖尿病肾病的临床研究[J].现代药物与临床，2016，31（4）：475-478.
[5]	石晓燕.用舒洛地特和前列地尔治疗老年2型糖尿病肾病的效果观察[J].当代医药论丛，2016，15（15）：77-78.
[6]	曹单单，刘素雁.血液透析联合舒洛地特治疗糖尿病肾病患者的疗效观察[J].临床肾脏病杂志，2015，15（1）：52-54.
[7]	胡猛，吕柏宁，周建国，等.培哚普利联合舒洛地特治疗老年早期糖尿病肾病疗效观察[J].西南国防医药，2010，20（5）：501-503.
[8]	庹艳红，郑卫华，卢金金，等.舒洛地特联合活性维生素D3治疗 IgA肾病的临床观察[J].医学研究杂志，2015，44（5）：150-152.
[9]	胡猛，吕柏宁，孟艳秋，等.舒洛地特联合厄贝沙坦治疗老年糖尿病肾病疗效观察[J].实用老年医学，2009，23（4）：276-278.
[10]	王扬天，彭丽，叶小珍，等.舒洛地特治疗糖尿病肾病合并视网膜病变的临床疗效观察[J].医学研究生学报，2010，23（12）：1269-1272.
[11]	曹立平.替米沙坦联合通心络胶囊对早期糖尿病肾病的疗效观察[J].河北医药，2011，33（24）：3727-3728.
[12]	黄宁.替米沙坦对高血压伴糖耐量受损内皮细胞功能的影响[J].海南医学，2009，20（2）：14-15.
[13]	陈端，侯伟宁，钟世勤.替米沙坦对使用美托洛尔治疗的慢性心力衰竭合并高血压、糖耐量受损患者糖代谢的影响研究[J].实用心脑肺血管病杂志，2014，22（8）：14-16.
[14]	项琼，宋恩峰，梅莎莎.银杏叶提取物联合舒洛地特治疗糖尿病肾病Ⅲ期患者的临床观察[J].微循环学杂志，2014，24（1）：27-29.
[15]	王彦，唐琳.舒洛地特注射液联合缬沙坦胶囊治疗糖尿病肾病的临床研究[J].中国临床药理学杂志，2016，32（21）：1953-1956.